Sam Chun Dang Pharm Co 000250.KQ · KRW

Its shares trade on KOSDAQ under the ticker 000250.KQ. It has been listed since 4 October 2000. In the fiscal year to 31 December 2025, it reported revenue of ₩231.81bn and net income of ₩5.26bn. At that date it held total assets of ₩561.23bn and shareholders' equity of ₩276.02bn.

SAM CHUN DANG PHARM Co., Ltd. engages in the manufacture of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2000-10-04. CO., LTD is a Korea-based company mainly engaged in the manufacture of prescription medicines. The Company’s products portfolio consists of antibiotics used for treatment of sepsis, respiratory diseases and others; circulatory disease medicines including cardiovascular and endocrine medicaments used for treatment of diabetes, hypertension, angina and others under the brand names of Glilazide and Atenolol; digestive medicines used for treatment of duodenal ulcer, gastritis and others; ophthalmological agents used for treatment of conjunctivitis, keratitis and other eye inflammation under the brand names of Ofus and Toracin, and anti-inflammatories used to release postoperative pains under the brand name Barotase and others.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Dae Yin YoonChairman, since 2022₩567.6m
• Mr. Yin Seok JeonPresident, Chief Executive Officer, Director, since 2018
• Mr. Se Yeong CheonVice President
• Mr. Tae Eun JangManaging Director
• Mr. Seong Ryong OhManaging Director
• Mr. Jeong Hwan ChoInternal Auditor, Director, since 2022
• Mr. Sang Ho ShimAssistant Managing Director
• Mr. Byeong Jip HaAssistant Managing Director
• Mr. Yin Hyeong LeeInternal Auditor
• Mr. Hyeong Jin YoonDirector
• Mr. Yong Gwan KimNon-Executive Independent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.